ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Glaxo claims vaccine advance

July 31, 2006 | APPEARED IN VOLUME 84, ISSUE 31

GlaxoSmithKline has released data showing that a vaccine it is developing for H5N1 avian flu achieved a high immune response at a low dose. Interim analysis of a clinical trial found that more than 80% of subjects who received a 3.8-mg dose of active ingredient demonstrated a "strong" immune response. The vaccine includes a proprietary response-boosting adjuvant. CEO Jean-Pierre Garnier says GSK expects to make a regulatory filing for the vaccine "in the coming months." Sanofi Pasteur reported in May on a developmental vaccine that was effective in two-thirds of patients at a 30-mg dose but in only about 40% of patients at a 7.5-mg dose.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment